An international research group recently demonstrated that the antibody NG101 promotes the regeneration of damaged spinal cord tissue. Now, under the leadership of scientists at the University of Zurich and Balgrist University Hospital, the group has revealed for the first time how the therapy actually works. With a boost from this novel antibody, new nerve fibers form functional connections once again, allowing patients to become more independent.